Table 1.

Statements on administration and on tapering/discontinuation of second-line TPO-RAs for treatment of ITP.

	Statement	% agreement
1	An early switch from corticosteroids to a TPO-RA has the dual advantage of sparing patients from corticosteroid abuse and improve long-term clinical outcomes.	100%
2A	Dose reduction (tapering) of TPO-RAs can be considered in patients with a stable response and platelet count >50 × 109/L (PR) that is maintained for at least 6 months in the absence of concomitant treatments.	54.5%
2B	Dose reduction (tapering) of TPO-RAs can be considered in patients with a stable response and platelet count >50 × 109/L (PR) that is maintained for at least 6 months in the absence of concomitant treatments.	63.6%
3	Dose reduction (tapering) of TPO-RAs can be considered in patients with a stable response and platelet count >100 × 109/L (CR) that is maintained for at least 6 months in the absence of concomitant treatments.	100%
4A	If TPO-RA treatment is given early, there is a greater chance of achieving partial or complete response.	72.7%
4B	Early treatment with a TPO-RA is associated with an increase in clinically significant response (partial or complete).	72.7%
5	Optimization of tapering and discontinuation of TPO-RA therapy in selected patients can improve the quality of life.	90.1%

CR, complete response; ITP, immune thrombocytopenia; PR, partial response; TPO-RA, thrombopoietin receptor agonists.